Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Surgery of the primary tumor does not improve survival in stage IV breast cancer.

Dominici L, Najita J, Hughes M, Niland J, Marcom P, Wong YN, Carter B, Javid S, Edge S, Burstein H, Golshan M.

Breast Cancer Res Treat. 2011 Sep;129(2):459-65. doi: 10.1007/s10549-011-1648-2. Epub 2011 Jun 29.

2.

Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.

Rossi V, Nolè F, Redana S, Adamoli L, Martinello R, Aurilio G, Verri E, Sapino A, Viale G, Aglietta M, Montemurro F.

Breast. 2014 Feb;23(1):44-9. doi: 10.1016/j.breast.2013.10.005. Epub 2013 Nov 7.

3.

Survival in stage I-III breast cancer patients by surgical treatment in a publicly funded health care system.

Fisher S, Gao H, Yasui Y, Dabbs K, Winget M.

Ann Oncol. 2015 Jun;26(6):1161-9. doi: 10.1093/annonc/mdv107. Epub 2015 Feb 23.

4.

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.

Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M.

J Clin Oncol. 2014 Mar 10;32(8):735-44. doi: 10.1200/JCO.2013.49.7693. Epub 2014 Jan 27.

5.

Are Cure Rates for Breast Cancer Improved by Local and Regional Anesthesia?

Tsigonis AM, Al-Hamadani M, Linebarger JH, Vang CA, Krause FJ, Johnson JM, Marchese E, Marcou KA, Hudak JM, Landercasper J.

Reg Anesth Pain Med. 2016 May-Jun;41(3):339-47. doi: 10.1097/AAP.0000000000000379.

PMID:
26928797
6.

Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival.

Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M.

Breast Cancer Res Treat. 2009 May;115(1):7-12. doi: 10.1007/s10549-008-0101-7. Epub 2008 Jun 26. Review.

PMID:
18581232
7.

Presence of symptoms and timing of surgery do not affect the prognosis of patients with primary metastatic breast cancer.

Ruiterkamp J, Voogd AC, Bosscha K, Roukema JA, Nieuwenhuijzen GA, Tjan-Heijnen VC, Ernst MF.

Eur J Surg Oncol. 2011 Oct;37(10):883-9. doi: 10.1016/j.ejso.2011.07.004. Epub 2011 Aug 16.

PMID:
21843923
8.

Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011.

Thomas A, Khan SA, Chrischilles EA, Schroeder MC.

JAMA Surg. 2016 May 1;151(5):424-31. doi: 10.1001/jamasurg.2015.4539.

PMID:
26629881
9.

SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation.

Ruiterkamp J, Voogd AC, Tjan-Heijnen VC, Bosscha K, van der Linden YM, Rutgers EJ, Boven E, van der Sangen MJ, Ernst MF; Dutch Breast Cancer Trialists' Group (BOOG).

BMC Surg. 2012 Apr 2;12:5. doi: 10.1186/1471-2482-12-5.

10.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group.

Lancet Oncol. 2016 Mar;17(3):367-77. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.

PMID:
26874901
11.

Impact of Surgery on Survival in Stage IV Breast Cancer.

AlJohani B, AlMalik O, Anwar E, Tulbah A, Alshabanah M, AlSyaed A, Ajarim D, ALTweigeri T.

Breast J. 2016 Nov;22(6):678-682. doi: 10.1111/tbj.12662. Epub 2016 Aug 26.

PMID:
27564998
12.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators.

Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11.

PMID:
23764181
13.

Primary tumor excision in stage IV breast cancer at diagnosis without influence on survival: a retrospective analysis and review of the literature.

Rosche M, Regierer AC, Schwarzlose-Schwarck S, Weigel A, Bangemann N, Schefe JH, Scholz CW, Possinger K, Eucker J.

Onkologie. 2011;34(11):607-12. doi: 10.1159/000334061. Epub 2011 Oct 28. Review.

PMID:
22104157
14.

Association of surgery with improved survival in stage IV breast cancer patients.

Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM.

Ann Surg. 2008 May;247(5):732-8. doi: 10.1097/SLA.0b013e3181656d32.

PMID:
18438108
15.

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.

Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ.

Cancer. 2014 Jul 1;120(13):1932-8. doi: 10.1002/cncr.28689. Epub 2014 Mar 26.

16.

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, Budrukkar A, Mittra I, Gupta S.

Lancet Oncol. 2015 Oct;16(13):1380-8. doi: 10.1016/S1470-2045(15)00135-7. Epub 2015 Sep 9.

PMID:
26363985
17.
18.

Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis.

Ruiterkamp J, Ernst MF, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC.

Eur J Surg Oncol. 2009 Nov;35(11):1146-51. doi: 10.1016/j.ejso.2009.03.012. Epub 2009 Apr 26.

PMID:
19398188
19.

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.

Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW.

Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18.

PMID:
22094934
20.

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M; LUX-Breast 1 study group.

Lancet Oncol. 2016 Mar;17(3):357-66. doi: 10.1016/S1470-2045(15)00540-9. Epub 2016 Jan 26.

PMID:
26822398

Supplemental Content

Support Center